Potential urinary biomarkers of nephrotoxicity in cyclophosphamide-treated rats investigated by NMR-based metabolic profiling

J Biochem Mol Toxicol. 2017 Mar;31(3). doi: 10.1002/jbt.21871. Epub 2016 Nov 21.

Abstract

The anticancer-drug cyclophosphamide (CP) is known to have nephrotoxicity. The aim of this study was to identify urinary biomarkers indicating CP-induced nephrotoxicity. We investigated the urine metabolic profiles using nuclear magnetic resonance spectrometry of rats administered with single high-doses of CP (0, 30, and 100 mg/kg body weight) and daily low-doses over a 4-week period (0, 1, 3, and 10 mg/kg body weight). Among 18 identified urinary metabolites, 2-oxoglutarate, citrate, hippurate, formate, valine, and alanine for short-term and 2-oxoglutarate, citrate, hippurate, isoleucine, leucine, allantoin, valine, and lysine for long-term were selected as potential biomarkers. Pathway-enrichment analysis suggested that the urinary metabolism of CP is related to valine, leucine, and isoleucine biosynthesis; taurine and hypotaurine metabolism; glyoxylate and dicarboxylate metabolism; citrate cycle; and alanine, aspartate, and glutamate metabolism, with high pathway impact. The potential biomarkers obtained in this study could be used to monitor CP-induced nephrotoxicity relative to dose and treatment time.

Keywords: 1H-NMR; Cyclophosphamide; Metabolic profiling; Nephrotoxicity; Urine.

MeSH terms

  • Animals
  • Biomarkers / urine*
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects*
  • Humans
  • Isoleucine / urine
  • Kidney / drug effects*
  • Kidney / pathology
  • Leucine / urine
  • Magnetic Resonance Spectroscopy
  • Metabolic Networks and Pathways / drug effects
  • Metabolomics*
  • Neoplasms / drug therapy
  • Neoplasms / urine*
  • Rats
  • Taurine / analogs & derivatives
  • Taurine / urine
  • Valine / urine

Substances

  • Biomarkers
  • Isoleucine
  • Taurine
  • hypotaurine
  • Cyclophosphamide
  • Leucine
  • Valine